CLC number:
On-line Access: 2024-11-05
Received: 2024-01-30
Revision Accepted: 2024-07-08
Crosschecked: 0000-00-00
Cited: 0
Clicked: 181
Zongye CAI, Xinrui QI, Dao ZHOU, Hanyi DAI, Abuduwufuer YIDILISI, Ming ZHONG, Lin DENG, Yuchao GUO, Jiaqi FAN, Qifeng ZHU, Yuxin HE, Cheng LI, Xianbao LIU, Jianan WANG. COMPERA 2.0 risk stratification in patients with severe aortic stenosis: implication for group 2 pulmonary hypertension[J]. Journal of Zhejiang University Science B, 1998, -1(-1): .
@article{title="COMPERA 2.0 risk stratification in patients with severe aortic stenosis: implication for group 2 pulmonary hypertension",
author="Zongye CAI, Xinrui QI, Dao ZHOU, Hanyi DAI, Abuduwufuer YIDILISI, Ming ZHONG, Lin DENG, Yuchao GUO, Jiaqi FAN, Qifeng ZHU, Yuxin HE, Cheng LI, Xianbao LIU, Jianan WANG",
journal="Journal of Zhejiang University Science B",
volume="-1",
number="-1",
pages="",
year="1998",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B2400057"
}
%0 Journal Article
%T COMPERA 2.0 risk stratification in patients with severe aortic stenosis: implication for group 2 pulmonary hypertension
%A Zongye CAI
%A Xinrui QI
%A Dao ZHOU
%A Hanyi DAI
%A Abuduwufuer YIDILISI
%A Ming ZHONG
%A Lin DENG
%A Yuchao GUO
%A Jiaqi FAN
%A Qifeng ZHU
%A Yuxin HE
%A Cheng LI
%A Xianbao LIU
%A Jianan WANG
%J Journal of Zhejiang University SCIENCE B
%V -1
%N -1
%P
%@ 1673-1581
%D 1998
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B2400057
TY - JOUR
T1 - COMPERA 2.0 risk stratification in patients with severe aortic stenosis: implication for group 2 pulmonary hypertension
A1 - Zongye CAI
A1 - Xinrui QI
A1 - Dao ZHOU
A1 - Hanyi DAI
A1 - Abuduwufuer YIDILISI
A1 - Ming ZHONG
A1 - Lin DENG
A1 - Yuchao GUO
A1 - Jiaqi FAN
A1 - Qifeng ZHU
A1 - Yuxin HE
A1 - Cheng LI
A1 - Xianbao LIU
A1 - Jianan WANG
J0 - Journal of Zhejiang University Science B
VL - -1
IS - -1
SP -
EP -
%@ 1673-1581
Y1 - 1998
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B2400057
Abstract: Background: COMPERA 2.0 risk stratification has been demonstrated to be useful in patients with precapillary pulmonary hypertension (PH). However, its suitability for patients at a risk for post-capillary PH, or PH associated with left heart disease (PH-LHD), is unclear. Aims: To investigate the use of COMPERA 2.0 in patients with severe aortic stenosis (SAS) undergoing transcatheter aortic valve replacement (TAVR), which are at risk for post-capillary PH. Methods: 327 eligible SAS patients undergoing TAVR between September 2015 to November 2020 in our institute were included. Patients before and after TAVR were classed into four strata using the COMPERA 2.0 risk score. The primary endpoint was all-cause mortality. Survival analysis was performed using Kaplan-Meier curves, log-rank test, and Cox proportional hazard models. Results: The study cohort had a median (interquartile range) age of 76 (70-80) years and a pulmonary arterial systolic pressure of 33 (27-43) mmHg before TAVR. The overall mortality was 11.9% during 26 (15-47) months of follow-up. Before TAVR, cumulative mortality was higher with an increase in the risk stratum level (Log-rank, both P < 0.001); one increase in the risk stratum level resulted in an increased risk of death (Hazard Ratio, HR 2.53, 95% confidential interval, CI 1.54 - 4.18, P < 0.001), which was independent of age, sex, estimated glomerular filtration rate, hemoglobin, albumin, and valve type (HR 1.76, 95% CI 1.01 - 3.07, P = 0.047). Similar results were found at 30 days after TAVR.Conclusions: COMPERA 2.0 can be a useful tool for risk stratification in patients with SAS undergoing TAVR, indicating its potential use in PH-LHD. Further validation is needed in patients with confirmed post-capillary PH by right heart catheterization.
Open peer comments: Debate/Discuss/Question/Opinion
<1>